here are 2 strategies for treatment of patients with atrial fibrillation (AF). One is the rate control and the other is rhythm control. Rate control adjusts ventricular responses during AF using -blockers, Ca antagonists and digitalis. Suppression of inappropriate increase in heart rate and regularization of RR intervals during AF are the target of rate control strategy. However, rhythm control restores and maintains sinus rhythm using antiarrhythmic drugs. Usually the presence of sinus rhythm increases cardiac functional reserve, prevents stroke events and improves quality of life. Hence, theoretically, rhythm control seems superior to rate control and rate control strategy is the second option after failure of rhythm control strategy.
Rhythm Control vs Rate Control Therapy
The large scale randomized study, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM), was done to determine which strategy was better for treatment of patients with AF. 1 Approximately 4,000 patients with baseline characteristics of high risk for stroke were enrolled and randomized to either rate or rhythm control strategy and followed up. The study showed that rhythm control strategy using antiarrhythmic drugs did not offer any survival advantages for patients with AF compared with rate control strategy and also revealed importance of warfarin usage for the prevention of stroke in both strategies. Most physicians who believed that rhythm control was better than rate control were disappointed at the results
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of AFFIRM. In the results of AFFIRM based on an intention-treat analysis, however, the rhythm control does not always mean the presence of sinus rhythm. Furthermore, AFFIRM sub-analysis based on an on-treatment analysis was reported. 2 The report clearly showed that the presence of sinus rhythm was associated with improved survival in patients with AF. The antiarrhythmic drug usage did not show any survival benefit if the patients already had sinus rhythm. The report suggested that any beneficial effects of currently available antiarrhythmic drugs could be offset by the drug's adverse effects. If we have more effective and safer antiarrhythmic drugs in the treatment of AF we might be able to show the superiority of rhythm control strategy to rate control strategy.
Conversion of Long-Lasting AF to Sinus Rhythm With Antiarrhythmic Drugs
Pharmacological cardioversion is effective for termination of AF lasting only a few days, but is of little help for termination of long-lasting AF. 3 Amiodarone is the only exception and may have some efficacy for conversion of persistent AF to sinus rhythm. 4 The long-lasting AF induces changes in ion channel properties such as decreasing protein levels for the L-type Ca channel and several K channels (Kv4.3, Kv1.5, HERG, minK and Kir3.1), which make pharmacological conversion more difficult in persistent AF than in paroxysmal AF. 5, 6 In a canine model of AF with atrial tachypacing, amiodarone was shown to prevent downregulation of L-type Ca channel and reversed pacinginduced shortening of atrial refractoriness. 7 However, clinical use of amiodarone is limited because of its serious extracardiac side-effects.
Bepridil is a multichannel blocker like amiodarone, and has both antianginal and antiarrhythmic effects. Several reports have shown that bepridil inhibits both L-and T-type Ca currents, as well as Na current in isolated cardiac myocytes. 8, 9 Bepridil also inhibits several K currents including rapid, slow and ultra-rapid components of delayed rectifier K current, muscarinic acetylcholine receptor-operated K current and ATP-sensitive K current. [10] [11] [12] [13] Bepridil prolongs atrial action potential duration and is expected to be effective for conversion of AF. 11 The K channel blocking actions are, however, supposed to increase a risk for prolongation of QT interval and torsades de pointes. 10 Perelman et al showed that bepridil was more effective than amiodarone in terminating established AF (≥3 months), but was associated with life-threatening ventricular arrhythmias. 14 They concluded that arrhythmogenic actions of bepridil make it unsuitable for treatment of AF. However, they administered bepridil at dosages of 200 to 600 mg/day, which were extremely higher compared with those used in Electrocardiogram and spectral analyses of fibrillation waves in a representative patient with conversion of atrial fibrillation (AF) by bepridil and aprindine. This 61-year-old male had persistent AF lasting 36 months preceded by drugresistant paroxysmal AF (18 months). He had apical type of hypertrophic cardiomyopathy and enlarged left atrium (48 mm). Before bepridil administration QTc was 0.44 and fine fibrillation waves were observed in V1. After a combination of bepridil and aprindine fibrillation waves became coarser in V1 and sinus rhythm was restored. During sinus rhythm QTc was 0.44. Mean fibrillation cycle length (FCL) calculated from the peak frequency was 141 ms before bepridil (Lower left) and increased to 207 ms after bepridil and aprindine therapy (Lower right). The peak frequency shifted to the left after a combination of bepridil and aprindine had been started. Japan (100-200 mg/day).
To minimize the adverse effect of bepridil without losing its efficacy, we chose a combination therapy with bepridil and aprindine. 15 Aprindine was selected as the additional drug because of its unique Na channel blocking properties. 16 As a class Ib antiarrhythmic drug similar to lidocain, aprindine counterbalance excessive QT prolongation induced by bepridil. Aprindine blocks Na channel mainly in the inactivated state; therefore prolongation of the action potential duration by bepridil would enhance Na channel blocking effect of aprindine on the atrial cells. In addition to class I antiarrhythmic drug action, aprindine causes a moderate reduction of delayed rectifier K current and hyperpolarization-activated inward current. 17 
Efficacy and Safety of Bepridil Alone or in Combination With Aprindine for Cardioversion of Long-Lasting AF
We studied 32 consecutive patients (23 men, mean age of 61±8 years) with AF lasting ≥3 months without a history of sinus node dysfunction. Patients received bepridil (200 mg/day) for 4 weeks after anticoagulation therapy. When sinus rhythm was not restored with bepridil and QT interval prolongation was not excessive (QTc <0.50 s and %increase <25% of the baseline value), oral aprindine (40 or 60 mg/day) was added to bepridil (Fig 1) . Fast Fourier transform analysis (20 consecutive 4,096 ms epochs with 50% overlap) was performed using lead V1 before and after bepridil administration. Fibrillation cycle length (FCL) was calculated from the peak frequency of each epoch.
Representative electrocardiograms (ECGs) and spectral analyses from a patient with pharmacological conversion by a combination of bepridil with aprindine are shown in Fig 2. With bepridil, FCL increased from 148±26 to 194±37 ms for responders and from 156±26 to 183±36 ms for nonresponders. Responders had greater increase in FCL by bepridil than non-responders (31±10% vs 17±5%, p<0.001). After bepridil treatment QTc interval increased from 0.39± 0.04 to 0.43±0.04 s in responders and from 0.41±0.04 to 0.46±0.06 s in non-responders. The increase in QTc interval with bepridil did not differ between responders and non-responders (11±14% vs 13±12%, NS).
In 10 out of 32 patients oral bepridil converted AF to sinus rhythm 19 days (7 to 28 days) after bepridil had been started (Phase I). Sixteen out of 22 patients who initially had failed to respond to bepridil received oral aprindine in addition to bepridil. In 11 out of 16 patients AF was terminated 11 days (4 to 21 days) after aprindine had been added to bepridil (Phase II). Six patients who had failed to respond to bepridil were followed without additional administration of aprindine. Only 1 of them restored sinus rhythm during Phase II. The final success rate of conversion with bepridil alone or in combination with aprindine was 69% (22 of 32 patients) and the time to conversion after starting bepridil was 30±12 days. The duration of AF was significantly shorter in responders than in non-responders (18±23 vs 118±74 months, p<0.001). Left ventricular ejection fraction and left atrial dimension did not differ between the 2 groups.
No adverse effects necessitating drug discontinuation occurred. However, bepridil dosage was reduced from 200 mg to 100 mg/day in 7 patients because of excessive QT prolongation and sinus bradycardia.
Frequency Analysis of Fibrillation Waves
During AF, precise manual measurements of fibrillation intervals are practically difficult and inaccurate. Several investigators analyzed frequency characteristics of fibrillation waves from surface ECG using QRST subtraction methods and approved that spectral analysis of surface ECG in AF is useful for quantification of fibrillation wave characteristics. 18 Bollmann et al reported that FCL was an accurate predictor of conversion of AF with a class III antiarrhythmic drug, ibutilide. 19 In our previous study, mean FCL obtained from intracardiac electrograms at the right atrial free wall was a good predictor of AF termination with class I antiarrhythmic drugs 20 similar to termination of AF with bepridil alone or in combination with aprindine. 15 Spectral analysis was introduced not only for measuring FCL but also for quantifying AF organization. 21 Area ratio of the spectral zone with the maximum power to the total spectral area between 3 and 12 Hz was calculated from power spectral analysis of each epoch (Fig 3) . The area ratio, which can represent the degree of AF organization, was termed fibrillation organization index (FOI). The FCL consists of refractory period and temporal excitable gap. However, FOI is related to spatial size of reentry circuit (pathway length), consisting of wavelength and spatial excitable gap. Power spectra showing multiple peaks and lower FOI might represent a greater number of circulating wavelets in the atria as compared with those with single peak pattern. Everett et al quantified AF organization using spectral analysis in a canine AF model. 22 They showed that defibrillation energy of AF was dependent on the degree of AF organization; the higher defibrillation energy was required for termination of AF with the less organized fibrillation waves. According to the multiple wavelets hypothesis, the number of wavelets varies as a result of variation in the rate of wavelets formation and extinction. 23 Drugs decreasing the number of wavelets may increase FOI and thereby increase the propensity for AF termination.
Mechanism of Termination With Antiarrhythmic Drugs With Respect to Fibrillation Waves
In vagally-induced canine AF, nifekalant (a class III antiarrhythmic drug) terminated AF in association with increases in both FCL and wavelength. However, pilsicainide (a class Ic drug) terminated AF without an increase in wavelength. 24 Wijffels et al measured wavelength using activation maps and found increases in both FCL and excitable gap and unchanged wavelength before termination of AF by class I or III drugs. 25 Kawase et al showed widening of excitable gap related to an increase in the core perimeter of acetylcholine-induced canine AF with pilsicainide. 26 During AF serial changes of FCL and FOI were analyzed before and after bepridil administration. A critical increase in both FCL and FOI was required for termination of longlasting persistent AF with bepridil alone or in combination with aprindine (Fig 4) . 21 The increase in FCL and FOI by bepridil alone might be attributable mainly to class III action to increase atrial refractoriness and a combination with aprindine can cause conduction delay at pivot points of functional reentry to increase FCL further. 26 These effects might lead to prolongation of FCL with fewer organized wavelets and increase the possibility of elimination of all circulating wavelets simultaneously. In patients who are scheduled for termination of persistent AF, investigation of FCL and FOI after drug administration is expected to be an useful predictor of success for pharmacological cardioversion.
Reversal of Atrial Remodeling
Human AF is associated with marked shortening of action potential duration and FCL as the progression of electrical remodeling. 27 A shortened FCL induced by persistent AF favors perpetuation of AF further. Pharmacological termination of long-lasting AF with bepridil alone or in combination with aprindine was preceded by a greater increase in FCL. The increase in FCL due to bepridil is in some part attributable to direct effects on several ion channels, but the time course of bepridil action (gradual increase in FCL and long pharmacological conversion interval) suggests the contribution of an additional effect on channel protein expression. Using a canine atrial tachypacing model, we have demonstrated that bepridil given after the development of remodeling reverses electrophysiological consequences and L-type Ca channel downregulation. 28 Amiodarone is also effective for pharmacological cardioversion of persistent AF and increases efficacy of electrical cardioversion because it might reverse already established atrial remodeling. 7 The delayed pharmacological cardioversion of AF by bepridil and amiodarone is attributed in part to such reversal of remodeling.
Recovery of Atrial Mechanical Function After Pharmacological Restoration of Sinus Rhythm
The electrical remodeling is reversible within a few days after restoration of sinus rhythm. 29 In contrast, recovery from mechanical stunning requires a longer time than recovery from electrical remodeling, depending on the duration of AF. 29 Manning et al reported that mechanical recovery was achieved within 1 week in patients with moderate AF duration (2-6 weeks) and within 1 month in patients with longer AF duration (>6 weeks). 30 Nishino et al demonstrated that atrial mechanical function showed no change over the first week and improved between 1 and 4 weeks after conversion in patients with longer duration of AF (≥6 months). 31 Compared with these reports, pharmacological cardioversion with bepridil or in combination with aprindine significantly enhanced the recovery of atrial mechanical function. 32 After pharmacological cardioversion of longlasting AF, atrial contraction recovered faster within 1 week and did not change further between the first week and the first month. Pharmacological conversion with bepridil might be beneficial to prevent the occurrence of thromboembolic events, because left atrial mechanical dysfunction after cardioversion is implicated in the development of thromboembolic stroke.
Post-cardioversion atrial stunning in humans seems to be the result of a functional loss of contraction as a result of reduction of L-type Ca current. 33 Findings from a canine model of chronic rapid atrial pacing suggested not only reduced systolic Ca transient but also impairing cellular Ca handling might contribute to atrial contractile dysfunction. 34 Both bepridil and amiodarone have T-type Ca channel blocking action similar to mibefradil that attenuates atrial tachycardia-induced electrical remodeling. 35 This T-type Ca channel blocking action might play a role in recovery of not only electrical remodeling but also post-cardioversion atrial stunning. In cultured rat ventricular myocytes bepridil increased Ca sensitivity of contractile proteins and offset negative inotropic effect of L-type Ca channel blocking action. 36 This Ca sensitizing effect might also contribute to the early recovery of atrial mechanical function after restoration of sinus rhythm.
Maintenance of Sinus Rhythm After Pharmacological Cardioversion of Persistent AF
As shown in Fig 5, sinus rhythm was maintained better in patients with pharmacological cardioversion with bepridil (83% at 12-month period) than in patients with electrical cardioversion (36% at 12-month period). 32 After successful pharmacological cardioversion some patients can have recurrences of AF but they could terminate spontaneously with continued administration of bepridil. Termination of recurrent AF by bepridil could be the results of prevention and reversal of atrial electrical remodeling. 37 However, electrical cardioversion terminates AF suddenly without affecting the remodeled AF substrate. Consequently, once AF recurs shortly after electrical cardioversion it may not terminate spontaneously. These differences in the atrial substrate after sinus restoration might contribute to the lower recurrence rate of persistent AF in patients with pharmacological cardioversion with bepridil compared with electrical one.
Two Types of Persistent AF
AF usually starts as paroxysmal type and transforms into persistent type. 38, 39 Mechanisms of paroxysmal AF mainly consist of initiating factors and the role of maintaining factors is less important. The role of maintaining factors are getting more important in association with the progression of AF. 40 We found that approximately one-third of persistent AF had been preceded by drug-refractory paroxysmal AF. 41 This type of persistent AF might have both initiating and maintaining factors. The remaining two-thirds of patients with persistent AF did not have any history of paroxysmal AF as a prelude. For instance, patients with mitral stenosis who have the large left atrium usually maintain sinus rhythm until they have triggering events of AF. Once triggering premature atrial beats induce AF, it hardly terminates spontaneously. This type of persistent AF depends mainly on maintaining factors caused by structural remodeling.
FCL after bepridil therapy was significantly shorter in patients with a history of paroxysmal AF than in those without; however, conversion rate was not different between them. 41 Maintenance of sinus rhythm at the 12-month period was 60% and lower in patients with a history of drug resistant paroxysmal AF. As shown in the representative case (Fig 2) , despite the history of frequent episodes of drug-resistant AF, the patient could maintain sinus rhythm very well after pharmacological cardioversion of persistent AF. These observations suggest that in some patients, perpetuation of AF in itself might decrease the activity of drug resistant initiating factors after pharmacological cardioversion. Although the mechanism of changes in initiating factors during persistent AF is not clear, bepridil therapy for pharmacological conversion of persistent AF could become a new therapeutic option irrespective of the history of drug resistant paroxysmal AF.
Safety Usage of K Channel Blockers
The adequate evaluation of QT interval is essential for safety use of K channel blockers. However, correction of QT interval by any heart rate adjustment methods might have some limitations. We made a nomogram of normal QT interval at various heart rates based on automatic measurements of 24-h Holter ECG recordings in 422 healthy individuals. 42 Evaluation of QT interval without correction formula using this nomogram is useful for QT interval measurement after administration of K channel blockers including bepridil. For safety usage of bepridil, the maximum dosage of bepridil should be limited to ≤200 mg/day, and serum K ≥4.0 mmol/L should be maintained with administration of inhibitors of the renin-angiotensin-aldosterone system. It is well known that both angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are effective for treatment of AF because of suppression of atrial structural remodeling. 43, 44 Combined use of a K channel blocker and a renin-angiotensin-aldosterone system inhibitor is expected to be useful and safe for pharmacological cardioversion of long-lasting AF.
Conclusion
Pharmacological restoration of sinus rhythm in patients with long-lasting AF could be a new therapeutic option. Although the precise mechanism is still unclear, reversal of the remodeled atria might play an important role for pharmacological cardioversion with bepridil. Fig 5. Kaplan -Meier curves for probability of remaining in sinus rhythm in pharmacological conversion with bepridil and electrical conversion (from reference 32). At the 12-month follow-up examination, 83% of the patients who had been converted to sinus rhythm pharmacologically using bepridil were free of recurrence of persistent atrial fibrillation, as compared with 36% of the patients who had been converted electrically without bepridil administration.
